Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Invested Capital (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Invested Capital for 7 consecutive years, with $67.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 3.37% year-over-year to $67.5 million, compared with a TTM value of $67.5 million through Dec 2025, down 3.37%, and an annual FY2025 reading of $67.5 million, down 3.37% over the prior year.
  • Invested Capital was $67.5 million for Q4 2025 at aTYR PHARMA, down from $80.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $117.4 million in Q3 2021 and bottomed at $40.8 million in Q2 2021.
  • Average Invested Capital over 5 years is $82.6 million, with a median of $80.8 million recorded in 2024.
  • The sharpest move saw Invested Capital soared 246.61% in 2021, then tumbled 34.68% in 2022.
  • Year by year, Invested Capital stood at $109.1 million in 2021, then crashed by 34.68% to $71.3 million in 2022, then rose by 26.91% to $90.5 million in 2023, then dropped by 22.81% to $69.8 million in 2024, then dropped by 3.37% to $67.5 million in 2025.
  • Business Quant data shows Invested Capital for ATYR at $67.5 million in Q4 2025, $80.2 million in Q3 2025, and $74.7 million in Q2 2025.